BeOne Medicines Ltd (ONC) ADR Each Representing 13 Ord Shares

Sell:$245.58Buy:$246.06$1.10 (0.45%)

NASDAQ:0.32%
Market closed | Prices delayed by at least 15 minutes
Sell:$245.58
Buy:$246.06
Change:$1.10 (0.45%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$245.58
Buy:$246.06
Change:$1.10 (0.45%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

BeiGene, Ltd. is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. The Company has an oncology pipeline of more than 50 investigational assets. Its products include BRUKINSA, TEVIMBRA, XGEVA, BLINCYTO, KYPROLIS, POBEVCY, and others. BRUKINSA is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). TEVIMBRA is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is engaged in the sale of XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen and POBEVCY in China under a license from Bio-Thera. The Company’s pipeline products include Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, Xaluritamig, and others.

Key people

John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Xiaobin Wu
President, Chief Operating Officer, General Manager, China
Xiaodong Wang
Co-Founder, Non-Executive Director
Aaron Rosenberg
Chief Financial Officer
Chan Lee
Senior Vice President, General Counsel
Lai Wang
Global Head of R&D
Ranjeev Krishana
Lead Non-Executive Independent Director
Olivier Brandicourt
Independent Non-Executive Director
Han Dugan
Non-Executive Independent Director
Michael J. Goller
Non-Executive Independent Director
Anthony C. Hooper
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    688235
  • Location
    Cayman Islands
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US07725L1026
  • Market cap
    $29.83bn
  • Employees
    11,075
  • Shares in issue
    115.06m
  • Exchange
    Shanghai Stock Exchange
  • Index
    Shanghai SE Composite Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.